Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.43 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12364210 | 0.97 | TDP1 (0.51) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL15329618 | 0.88 | MAPT (0.51) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL15340917 | 0.85 | TSHR (0.54) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL15329958 | 0.85 | TDP1 (0.49) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL7657590 | 0.84 | TDP1 (0.58) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2544759 | 0.82 | TDP1 (0.49) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL9069658 | 0.82 | ALDH1A1 (0.56) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL15330297 | 0.81 | ALDH1A1 (0.47) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL10713235 | 0.80 | TDP1 (0.58) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2265147 | 0.78 | CSNK2A1 (0.47) | TDP1ALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2352374-B1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2352374-B1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8563746-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563746-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563746-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2013-10-22 | — | — | US | disclosed |
| US-20110195964-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2011-08-11 | — | — | US | disclosed |
| US-20110195964-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2011-08-11 | — | — | US | disclosed |
| US-20110195964-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2011-08-11 | — | — | US | disclosed |
| WO-2010051176-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195964-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | TDP1 3641/4885ALDH1A1 1887/4885MAPT 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.